Across TCGA pan-cancer cohorts, SUPT20HL1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SUPT20HL1 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher SUPT20HL1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SUPT20HL1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SCLC show a favorable association.

LUSC, STAD, and UCEC are the cancer types where SUPT20HL1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	III,IV	0.126	0.664	.008	19	view →
STAD	OS	Median	All	0.184	0.730	.002	18	view →
UCEC	DFS	Median	All	1.000	0.830	.022	8	view →
SCLC	OS	Median	All	1.000	0.317	.020	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: SUPT20HL1 tumor-vs-normal RNA expression · all SUPT20HL1 data types